It's been a sad week for Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), who've watched their investment drop 17% to US$0.44 in the week since the company reported its yearly result. The statutory results were not great - while revenues of US$18m were in line with expectations,Ekso Bionics Holdings lost US$0.56 a share in the process. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

Taking into account the latest results, the consensus forecast from Ekso Bionics Holdings' two analysts is for revenues of US$22.0m in 2025. This reflects a huge 23% improvement in revenue compared to the last 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 38% to US$0.32. Before this earnings announcement, the analysts had been modelling revenues of US$23.6m and losses of US$0.23 per share in 2025. So it's pretty clear the analysts have mixed opinions on Ekso Bionics Holdings after this update; revenues were downgraded and per-share losses expected to increase.

The average price target lifted 64% to US$9.00, clearly signalling that the weaker revenue and EPS outlook are not expected to weigh on the stock over the longer term.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. It's clear from the latest estimates that Ekso Bionics Holdings' rate of growth is expected to accelerate meaningfully, with the forecast 23% annualised revenue growth to the end of 2025 noticeably faster than its historical growth of 13% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 7.8% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Ekso Bionics Holdings to grow faster than the wider industry.

The Bottom Line

The most important thing to take away is that the analysts increased their loss per share estimates for next year. They also downgraded Ekso Bionics Holdings' revenue estimates, but industry data suggests that it is expected to grow faster than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.

With that in mind, we wouldn't be too quick to come to a conclusion on Ekso Bionics Holdings. Long-term earnings power is much more important than next year's profits. We have analyst estimates for Ekso Bionics Holdings going out as far as 2027, and you can see them free on our platform here.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.